In-house GMP production
Since 2006, CureVac has its own GMP-compliant production plant for large RNA molecules designated for medical application. We were the first company worldwide to develop this process and obtain regulatory approval. The company’s own plant has been validated by government authorities (e.g. PEI, FDA, Swissmedic) and has received manufacturing authorization for numerous clinical studies.
Manufacturing is subject to strict regulatory controls. Good Manufacturing Practice (GMP) comprises a continuously high level of product quality, documentation of all work steps, as well as the regular inspection of laboratories, equipment, supplier operations and source materials.
A broad patent basis protects the standardized production process for RNA active ingredients, developed by CureVac.